Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDMENT #1 TO SUITE...Suite Retention and Development Agreement • November 5th, 2020 • Translate Bio, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT #1 (the “Amendment”) to the SUITE RETENTION AND DEVELOPMENT AGREEMENT dated September 9, 2019 (the “Agreement”) is made and entered into as of September 22, 2020 (the “Amendment Effective Date”), by and between Albany Molecular Research, Inc. with a place of business at 26 Corporate Circle, Albany, New York 12203 (“AMRI”) and Translate Bio, Inc. with a place of business at 29 Hartwell Avenue, Lexington, Massachusetts 02421 (“Translate Bio”). For purposes of this Amendment, AMRI and Translate Bio are each a “Party” and collectively, the “Parties.”
SUITE RETENTION AND DEVELOPMENT AGREEMENTSuite Retention and Development Agreement • November 6th, 2019 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This SUITE RETENTION AND DEVELOPMENT AGREEMENT (the “Agreement”) is made this 9th day of September, 2019 (the “Effective Date”), by and between Albany Molecular Research, Inc. (“AMRI”), with a place of business at 26 Corporate Circle, Albany, NY 12203 and Translate Bio, Inc. (“Translate Bio”), with a place of business at 29 Hartwell Avenue, Lexington, MA 02421. For purposes of this Agreement, AMRI and Translate Bio are each a “Party” and collectively, the “Parties.”
